Trial Profile
Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs Huperzine A (Primary)
- Indications Seizures
- Focus Proof of concept; Therapeutic Use
- Acronyms FIAS
- Sponsors Biscayne Neurotherapeutics; Supernus Pharmaceuticals
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 13 Apr 2021 Planned End Date changed from 30 Nov 2018 to 30 Dec 2026.
- 13 Apr 2021 Planned primary completion date changed from 30 Nov 2018 to 30 Dec 2026.